Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-29 22:00 | 2026-06-25 | ATAI | AtaiBeckley Inc. | Craig Kevin James | Officer | OPT+S | $4.51 | 42,579 | $192,031 | 8,437 |
| 2026-06-29 21:23 | 2026-06-29 | CYTK | CYTOKINETICS INC | Lee Sung | Officer | OPT+S | $85.00 | 3,134 | $266,390 | 63,221 |
| 2026-06-29 20:52 | 2026-06-25 | IMNM | Immunome Inc. | Lechleider Robert | Officer | OPT+S | $19.85 | 55,000 | $1,091,662 | 15,805 |
| 2026-06-29 20:33 | 2026-06-26 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $543.97 | 9,500 | $5,167,734 | 40,513 |
| 2026-06-29 20:34 | 2026-06-29 | IMNN | Imunon, Inc. | Eylward Susan | Officer | SELL | $1.75 | 11,800 | $20,674 | 2,896 |
| 2026-06-29 20:17 | 2026-06-26 | ZLAB | Zai Lab Ltd | Chen Yajing | Officer | OPT+S | $17.46 | 2,264 | $39,532 | 35,691 |
| 2026-06-29 20:17 | 2026-06-26 | ZLAB | Zai Lab Ltd | Du Ying | Director, Officer | OPT+S | $17.46 | 24,543 | $428,545 | 1,192,840 |
| 2026-06-29 20:18 | 2026-06-26 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | Officer | OPT+S | $17.46 | 4,103 | $71,642 | 30,346 |
| 2026-06-29 20:02 | 2026-06-26 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | Director, Officer | BUY | $0.99 | 10,000 | $9,900 | 421,421 |
| 2026-06-29 14:41 | 2026-06-11 | PBLS | Parabilis Medicines, Inc. | Levy Guy | 10% owner | BUY | $20.00 | 500,000 | $10,000,000 | 652,000 |
| 2026-06-29 12:45 | 2026-06-25 | CALC | CalciMedica, Inc. | Middleton Fred A | Director, 10% owner | BUY | $0.80 | 248,972 | $199,999 | 1,063,272 |
| 2026-06-27 01:31 | 2026-06-25 | SYRE | Spyre Therapeutics, Inc. | Burrows Scott L | Officer | OPT+S | $87.13 | 15,000 | $1,307,000 | 97,994 |
| 2026-06-27 00:44 | 2026-06-25 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | Director, Officer, 10% owner | SELL | $3.04 | 11,156 | $33,920 | 105,989 |
| 2026-06-26 23:40 | 2026-06-24 | FTH | Sensei Biotherapeutics, Inc. | STEPHENSON BRIAN C | Officer | BUY | $25.65 | 15,641 | $401,268 | 33,054 |
| 2026-06-26 23:09 | 2026-06-25 | IONS | IONIS PHARMACEUTICALS INC | Swayze Eric | Officer | SELL | $79.18 | 10,602 | $839,492 | 21,759 |
| 2026-06-26 23:09 | 2026-06-24 | IONS | IONIS PHARMACEUTICALS INC | Monia Brett P | Director, Officer | OPT+S | $79.70 | 85,637 | $6,825,526 | 245,571 |
| 2026-06-26 22:13 | 2026-06-24 | ROIV | Roivant Sciences Ltd. | Venker Eric | Officer | OPT+S | $33.16 | 200,000 | $6,631,260 | 1,613,063 |
| 2026-06-26 21:20 | 2026-06-24 | PTCT | PTC THERAPEUTICS, INC. | Almstead Neil Gregory | Officer | OPT+S | $85.78 | 26,283 | $2,254,464 | 60,137 |
| 2026-06-26 21:09 | 2026-06-24 | PRAX | Praxis Precision Medicines, Inc. | DeSimone Jill | Director | OPT+S | $311.32 | 11,600 | $3,611,335 | 2,337 |
| 2026-06-26 21:15 | 2026-06-24 | QURE | uniQure N.V. | Kapusta Matthew C | Director, Officer | OPT+S | $50.02 | 35,412 | $1,771,174 | 519,227 |
| 2026-06-26 21:00 | 2026-06-25 | VTRS | Viatris Inc | Campbell Paul | Officer | SELL | $16.17 | 50,076 | $809,784 | 316,212 |
| 2026-06-26 20:32 | 2026-06-25 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $550.40 | 9,500 | $5,228,772 | 40,513 |
| 2026-06-26 20:15 | 2026-06-25 | DYN | Dyne Therapeutics, Inc. | Lucera Erick | Officer | SELL | $20.37 | 2,362 | $48,114 | 121,563 |
| 2026-06-26 20:03 | 2026-06-25 | INSM | INSMED Inc | Lewis William | Director, Officer | OPT+S | $103.32 | 21,398 | $2,210,762 | 258,917 |
| 2026-06-26 12:40 | 2026-06-23 | DYN | Dyne Therapeutics, Inc. | Rhodes Jason P | Director | SELL | $21.09 | 267,760 | $5,646,496 | 1,081,044 |
| 2026-06-25 23:06 | 2026-06-23 | ADTX | Aditxt, Inc. | Takeover Time 2026 LLC | 10% owner | SELL | $0.02 | 3,420,439 | $68,409 | 0 |
| 2026-06-25 22:38 | 2026-06-25 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | Officer | OPT+S | $20.06 | 28,935 | $580,506 | 13,579 |
| 2026-06-25 22:49 | 2026-06-25 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Officer | SELL | $20.00 | 5,394 | $107,880 | 115,005 |
| 2026-06-25 21:24 | 2026-06-23 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Officer | OPT+S | $18.00 | 1,450 | $26,100 | 51,776 |
| 2026-06-25 21:11 | 2026-06-23 | RPRX | Royalty Pharma plc | Hite Christopher | Officer | SELL | $54.40 | 150,000 | $8,159,280 | 559,399 |
| 2026-06-25 21:13 | 2026-06-24 | RPRX | Royalty Pharma plc | Urist Marshall | Officer | SELL | $55.18 | 9,098 | $502,067 | 9,099 |
| 2026-06-25 21:14 | 2026-06-23 | ONC | BeOne Medicines Ltd. | Wang Lai | Officer | SELL | $276.74 | 1,068 | $295,553 | 0 |
| 2026-06-25 21:15 | 2026-06-23 | ONC | BeOne Medicines Ltd. | OYLER JOHN | Director, Officer | SELL | $273.78 | 3,410 | $933,592 | 0 |
| 2026-06-25 21:15 | 2026-06-23 | ONC | BeOne Medicines Ltd. | Wu Xiaobin | Officer | SELL | $276.26 | 1,292 | $356,927 | 0 |
| 2026-06-25 20:39 | 2026-06-24 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $548.69 | 9,500 | $5,212,520 | 40,513 |
| 2026-06-25 20:30 | 2026-06-24 | LITS | Lite Strategy, Inc. | Flynn James P | Director | BUY | $0.86 | 25,000 | $21,388 | 125,000 |
| 2026-06-25 20:06 | 2026-06-23 | GALT | GALECTIN THERAPEUTICS INC | Jamil Khurram | Officer | OPT+S | $3.14 | 7,557 | $23,729 | 0 |
| 2026-06-25 20:10 | 2026-06-23 | PTGX | Protagonist Therapeutics, Inc | Waddill William D. | Director | OPT+S | $117.94 | 9,000 | $1,061,460 | 7,825 |
| 2026-06-24 20:10 | 2026-06-22 | NAMS | NewAmsterdam Pharma Co N.V. | Kooij Louise Frederika | Officer | OPT+S | $30.20 | 40,000 | $1,208,160 | 24,353 |
| 2026-06-24 20:05 | 2026-06-22 | ZLAB | Zai Lab Ltd | Lis William | Director | SELL | $18.09 | 7,040 | $127,354 | 50,437 |
| 2026-06-25 01:26 | 2026-06-22 | KARD | Kardigan, Inc. | HRTG GPE, LLC | 10% owner | BUY | $16.00 | 3,125,000 | $50,000,000 | 14,866,868 |
| 2026-06-25 00:37 | 2026-06-22 | OTLC | Oncotelic Therapeutics, Inc. | Trieu Vuong | Director, Officer, 10% owner | BUY | $0.05 | 255,000 | $11,475 | 93,694,319 |
| 2026-06-25 00:34 | 2026-06-22 | IRON | Disc Medicine, Inc. | Yu Jonathan Yen-Wen | Officer | OPT+S | $72.66 | 9,700 | $704,795 | 54,324 |
| 2026-06-25 00:09 | 2026-06-22 | KRRO | Korro Bio, Inc. | FORMELA JEAN FRANCOIS | Director | SELL | $14.34 | 171,405 | $2,458,582 | 169,556 |
| 2026-06-24 23:59 | 2026-06-22 | EVMN | Evommune, Inc. | Pena Luis C. | Director, Officer | SELL | $22.71 | 7,438 | $168,917 | 630,458 |
| 2026-06-25 00:00 | 2026-06-22 | CAPR | CAPRICOR THERAPEUTICS, INC. | Bergmann Anthony | Officer | OPT+S | $30.00 | 900 | $27,000 | 11,223 |
| 2026-06-25 00:00 | 2026-06-22 | CAPR | CAPRICOR THERAPEUTICS, INC. | Krasney Karen | Officer | OPT+S | $30.00 | 900 | $27,000 | 30,547 |
| 2026-06-25 00:00 | 2026-06-22 | EVMN | Evommune, Inc. | Patel Jeegar Pravinkumar | Officer | OPT+S | $22.50 | 1,488 | $33,480 | 46,403 |
| 2026-06-25 00:00 | 2026-06-22 | EVMN | Evommune, Inc. | Drew Janice Suzann | Officer | OPT+S | $22.63 | 20,000 | $452,600 | 67,794 |
| 2026-06-24 23:24 | 2026-06-22 | SEPN | Septerna, Inc. | Long Daniel D. | Officer | OPT+S | $35.51 | 15,000 | $532,581 | 96,412 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.